Revelation Biosciences, Inc. (REVB) Financials

REVB Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 15.0 million 2.1 million
Dec. 31, 2025 11.6 million 2.7 million
Sept. 30, 2025 12.9 million 1.9 million
June 30, 2025 5.4 million 1.6 million

REVB Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -3.3 million 470997
Dec. 31, 2025 -2.0 million 370166
Sept. 30, 2025 -1.6 million 874
June 30, 2025 -1.9 million 873

REVB Net Income

Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 -3.0 million
Dec. 31, 2025 -2.5 million
Sept. 30, 2025 -1.9 million
June 30, 2025 -2.4 million

REVB Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 14.1 million 638183 -
Dec. 31, 2025 10.7 million - 746784
Sept. 30, 2025 12.7 million - -
June 30, 2025 5.2 million - -

REVB Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 3.2 million
Dec. 31, 2025 620800
Sept. 30, 2025 2.6 million
June 30, 2025 802670

REVB Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 71879 1.4 million 1.7 million -
Dec. 31, 2025 - 964190 1.6 million -
Sept. 30, 2025 - 922857 1.0 million -
June 30, 2025 - 1.3 million 1.1 million -

REVB Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 7203
Dec. 31, 2025 - 5852
Sept. 30, 2025 - 6765
June 30, 2025 - 7220

REVB

Price: $0.98

52 week price:
0.88
12.88

Earnings Per Share: -23.95 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 562000

Market Capitalization: 3.9 million

Links: